Nov 14, 2023 4:15pm EST Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
Oct 23, 2023 7:03am EDT Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
Sep 06, 2023 7:03am EDT Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
Aug 14, 2023 5:36pm EDT Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
Jul 20, 2023 7:03am EDT Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
Jul 18, 2023 7:03am EDT Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
Jun 29, 2023 5:04pm EDT Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
Jun 16, 2023 7:38am EDT Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
May 16, 2023 8:29am EDT Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
